These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 11140685)

  • 81. Correction: Lesion of the subiculum reduces the spread of amyloid beta pathology to interconnected brain regions in a mouse model of Alzheimer's disease.
    George S; Rönnbäck A; Gouras GK; Petit GH; Grueninger F; Winblad B; Graff C; Brundin P
    Acta Neuropathol Commun; 2024 Feb; 12(1):26. PubMed ID: 38355705
    [No Abstract]   [Full Text] [Related]  

  • 82. [Retracted] Cognitive improvements and reduction in amyloid plaque deposition by saikosaponin D treatment in a murine model of Alzheimer's disease.
    Zhou L; Huang JY; Zhang D; Zhao YL
    Exp Ther Med; 2024 Oct; 28(4):387. PubMed ID: 39161615
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Galantamine protects against beta amyloid peptide-induced DNA damage in a model for Alzheimer's disease.
    Castillo WO; Aristizabal-Pachon AF
    Neural Regen Res; 2017 Jun; 12(6):916-917. PubMed ID: 28761423
    [No Abstract]   [Full Text] [Related]  

  • 84. Recent advances in transgenic model development for Alzheimer's disease.
    Sommer B
    Expert Opin Investig Drugs; 1998 Dec; 7(12):2017-25. PubMed ID: 15991944
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Cross-interactions between the Alzheimer disease amyloid-β peptide and other amyloid proteins. A FURTHER ASPECT OF THE AMYLOID CASCADE HYPOTHESIS.
    Luo J; Wärmländer SKTS; Gräslund A; Abrahams JP
    J Biol Chem; 2017 Feb; 292(5):2046. PubMed ID: 28159759
    [No Abstract]   [Full Text] [Related]  

  • 86. The β-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing.
    Kung HF
    ACS Med Chem Lett; 2012 Apr; 3(4):265-7. PubMed ID: 24936237
    [No Abstract]   [Full Text] [Related]  

  • 87. Corrigendum to "LMD proteomics provides evidence for hippocampus field-specific motor protein abundance changes with relevance to Alzheimer's disease" [BBAPAP 1865 (6) (2017) 703-714].
    Schrötter A; Oberhaus A; Kolbe K; Seger S; Mastalski T; El Magraoui F; Hoffmann-Posorske E; Bohnert M; Deckert J; Braun C; Graw M; Schmitz C; Arzberger T; Loosse C; Heinsen H; Meyer HE; Müller T
    Biochim Biophys Acta Proteins Proteom; 2018 Apr; 1866(4):580. PubMed ID: 29429852
    [No Abstract]   [Full Text] [Related]  

  • 88. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.
    Morgan D; Diamond DM; Gottschall PE; Ugen KE; Dickey C; Hardy J; Duff K; Jantzen P; DiCarlo G; Wilcock D; Connor K; Hatcher J; Hope C; Gordon M; Arendash GW
    Nature; 2000 Dec 21-28; 408(6815):982-5. PubMed ID: 11140686
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695.
    Chishti MA; Yang DS; Janus C; Phinney AL; Horne P; Pearson J; Strome R; Zuker N; Loukides J; French J; Turner S; Lozza G; Grilli M; Kunicki S; Morissette C; Paquette J; Gervais F; Bergeron C; Fraser PE; Carlson GA; George-Hyslop PS; Westaway D
    J Biol Chem; 2001 Jun; 276(24):21562-70. PubMed ID: 11279122
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.
    Walsh DM; Klyubin I; Fadeeva JV; Cullen WK; Anwyl R; Wolfe MS; Rowan MJ; Selkoe DJ
    Nature; 2002 Apr; 416(6880):535-9. PubMed ID: 11932745
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.
    Hardy J; Selkoe DJ
    Science; 2002 Jul; 297(5580):353-6. PubMed ID: 12130773
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.
    Nicoll JA; Wilkinson D; Holmes C; Steart P; Markham H; Weller RO
    Nat Med; 2003 Apr; 9(4):448-52. PubMed ID: 12640446
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization.
    Orgogozo JM; Gilman S; Dartigues JF; Laurent B; Puel M; Kirby LC; Jouanny P; Dubois B; Eisner L; Flitman S; Michel BF; Boada M; Frank A; Hock C
    Neurology; 2003 Jul; 61(1):46-54. PubMed ID: 12847155
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.
    Gilman S; Koller M; Black RS; Jenkins L; Griffith SG; Fox NC; Eisner L; Kirby L; Rovira MB; Forette F; Orgogozo JM;
    Neurology; 2005 May; 64(9):1553-62. PubMed ID: 15883316
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.
    Dodart JC; Bales KR; Gannon KS; Greene SJ; DeMattos RB; Mathis C; DeLong CA; Wu S; Wu X; Holtzman DM; Paul SM
    Nat Neurosci; 2002 May; 5(5):452-7. PubMed ID: 11941374
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders.
    Vellas B; Black R; Thal LJ; Fox NC; Daniels M; McLennan G; Tompkins C; Leibman C; Pomfret M; Grundman M;
    Curr Alzheimer Res; 2009 Apr; 6(2):144-51. PubMed ID: 19355849
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.
    Holmes C; Boche D; Wilkinson D; Yadegarfar G; Hopkins V; Bayer A; Jones RW; Bullock R; Love S; Neal JW; Zotova E; Nicoll JA
    Lancet; 2008 Jul; 372(9634):216-23. PubMed ID: 18640458
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Pathways towards and away from Alzheimer's disease.
    Mattson MP
    Nature; 2004 Aug; 430(7000):631-9. PubMed ID: 15295589
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Reversible memory loss in a mouse transgenic model of Alzheimer's disease.
    Kotilinek LA; Bacskai B; Westerman M; Kawarabayashi T; Younkin L; Hyman BT; Younkin S; Ashe KH
    J Neurosci; 2002 Aug; 22(15):6331-5. PubMed ID: 12151510
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Alzheimer's disease: the amyloid cascade hypothesis.
    Hardy JA; Higgins GA
    Science; 1992 Apr; 256(5054):184-5. PubMed ID: 1566067
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.